Medinol and Ariad form $39.25 million DES deal
This article was originally published in Clinica
Executive Summary
Medinol and Ariad Pharmaceuticals have linked up to develop stents and other medical devices that deliver Ariad's mTOR inhibitor, AP23573 as a means of preventing once-narrowed arteries from becoming re-clogged.